Point72 Asset Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Point72 Asset Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-41	Closed	-$74	–	2998
2023 Q2	$74	Buy	+41	New	+$75	﹤0.01%	2064
2022 Q3	–	Sell	-266,400	Closed	-$818K	–	1821
2022 Q2	$818K	Sell	266,400 -165,734	-38%	-$1.01M	﹤0.01%	1116
2022 Q1	$3.12M	Buy	432,134 +294,900	+215%	+$2.9M	0.01%	797
2021 Q4	$2.25M	Buy	+137,234	New	+$1.6M	0.01%	805

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 Asset Management's PRDS Position: Q3 2023 in Review

Point72 Asset Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 41 shares — an estimated $74 sold.

Point72 Asset Management first reported a position in PRDS in Q4 2021 and held it in 4 quarters. The position peaked at $3.12M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Point72 Asset Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Point72 Asset Management sold 41 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $74.
Point72 Asset Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Point72 Asset Management's Pardes Biosciences, Inc. Common Stock position peaked at $3.12M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.